Pharmalot

By  Ed Silverman

Taking stock of the drug industry, from the lab to the medicine chest. Sign up for the newsletter here.

Pharmalot

Pharmalittle: E.U. health chief calls Trump freeloading claim ‘fake news’; one drug maker says no to Right to Try

By Ed Silverman

Gottlieb Generic Drugs
Pharmalot

Frustrated at the pace of biosimilar development, FDA yanks a draft guidance

By Ed Silverman

Oxycodone script
Pharmalot

Canada looks to restrict how drug makers market opioids

By Ed Silverman

Pharmalot

Pharmalittle: A ‘right to try’ drug may cost $300,000; a rash of shortages for a new shingles vaccine

By Ed Silverman

Prescription Medication
Pharmalot

Consumer group petitions FDA to yank a widely prescribed gout drug over heart risks

By Ed Silverman

Pharmalot
Pharmalot

European Parliament restricts antibiotic use in food-producing livestock

By Ed Silverman

Pharmalot

Pharmalittle: A campaign downplays concerns over antibiotics given animals; U.K. parents step up fight over Vertex drug

By Ed Silverman

FDA Campus
Pharmalot

FDA says drug shortages fell last year, but don’t blame the agency for persistent problems

By Ed Silverman

Pharmalot

Pharmalittle: Valeant suffers a setback; CVS will use the Postal Service to deliver meds to your door

By Ed Silverman

Pharmalot

Pharmalittle: Chinese companies poaching big pharma talent; a battle over generic Suboxone looms

By Ed Silverman

Oxycodone
Pharmalot

Investor coalitions finding success pushing drug makers on pricing and opioid distribution

By Ed Silverman

Pharmalot
Pharmalot

‘Right-to-try’ law may have been unnecessary with previous success of FDA program, study argues

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Bristol cancer drug is approved in China; Teva gets a headache over migraine trial flops

By Ed Silverman

Prison
Pharmalot

Can a federal drug discount program unlock savings for state prisons?

By Ed Silverman

Pharmalot

Pharmalittle: Feds fight bid to disclose opioid shipments; Allergan moves to appease critics

By Ed Silverman

Hydrocodone
Pharmalot

The DEA is playing ‘whack-a-mole’ as it tries to stamp out the opioid crisis

By Ed Silverman

FDA Rare Disease
Pharmalot

A bill would preserve the status quo of a contentious drug discount program for hospitals

By Ed Silverman

Pharmalot

Pharmalittle: Celgene issues a mea culpa; Azar remains adamant that Medicare should not negotiate prices

By Ed Silverman

FDA campus
Pharmalot

The trouble with those post-marketing studies required by the FDA

By Ed Silverman

Pharmalot

Pharmalittle: Another Alzheimer’s drug failure; HHS wants pharma to voluntarily lower prices

By Ed Silverman

Clinical trials results for patients
Pharmalot

Clinical trial participants may not trust pharma, but they’re willing to share their data, anyway

By Ed Silverman

Pharmalot

Pharmalittle: An ALS drug may become available under ‘right to try’; Takeda shareholders look to derail Shire deal

By Ed Silverman

AbbVie California
Pharmalot

AbbVie is reprimanded by the FDA for failing to properly probe death complaints

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pfizer
Pharmalot

Pfizer wins appeal against record price-gouging fine set by U.K. antitrust watchdog

By Ed Silverman

Pharmalot

Pharmalittle: Novo Nordisk plans thousands of layoffs; Will former Allergan CEO return as chairman?

By Ed Silverman

Drug prices
Pharmalot

Lundbeck agrees to pay $52 million to resolve probe into using charities to assist patients

By Ed Silverman

Pharmalot

What Trump pushback? Bayer takes hefty price hikes on two cancer drugs in just six months

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy